Stephen M Husbands

List of Publications by Year
in descending order

143	4,235	134610	162838
papers	citations	34 h-index	57 g-index

159	159	159	4509
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	PPL-138 (BU10038): A bifunctional NOP/mu partial agonist that reduces cocaine self-administration in rats. Neuropharmacology, 2022, 211, 109045.	2.0	6
2	Countermeasures for Preventing and Treating Opioid Overdose. Clinical Pharmacology and Therapeutics, 2021, 109, 578-590.	2.3	38
3	The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 287-299.	1.3	8
4	Sex differences in the effect of chronic delivery of the buprenorphine analog BU08028 on heroin relapse and choice in a rat model of opioid maintenance. British Journal of Pharmacology, 2021, , .	2.7	15
5	Longâ€term antagonism and allosteric regulation of mu opioid receptors by the novel ligand, methocinnamox. Pharmacology Research and Perspectives, 2021, 9, e00887.	1.1	9
6	The development and validation of a human screening model of tobacco abstinence. Drug and Alcohol Dependence, 2020, 206, 107720.	1.6	1
7	A novel G proteinâ€biased agonist at the Î¼ opioid receptor induces substantial receptor desensitisation through G proteinâ€coupled receptor kinase. British Journal of Pharmacology, 2020, , .	2.7	7
8	Methocinnamox (MCAM) antagonizes the behavioral suppressant effects of morphine without impairing delayed matching-to-sample accuracy in rhesus monkeys. Psychopharmacology, 2020, 237, 3057-3065.	1.5	8
9	Pleiotropic Effects of Kappa Opioid Receptor-Related Ligands in Non-human Primates. Handbook of Experimental Pharmacology, 2020, 271, 435-452.	0.9	3
10	Effects of acute and repeated treatment with methocinnamox, a mu opioid receptor antagonist, on fentanyl self-administration in rhesus monkeys. Neuropsychopharmacology, 2020, 45, 1986-1993.	2.8	15
11	Pharmacological Properties of Î´-Opioid Receptorâ€“Mediated Behaviors: Agonist Efficacy and Receptor Reserve. Journal of Pharmacology and Experimental Therapeutics, 2020, 374, 319-330.	1.3	13
12	OREX-1019: A Novel Treatment of Opioid Use Disorder and Relapse Prevention. Journal of Pharmacology and Experimental Therapeutics, 2020, 372, 205-215.	1.3	11
13	Synthetic Cannabinoid Receptor Agonists Detection Using Fluorescence Spectral Fingerprinting. Analytical Chemistry, 2019, 91, 12971-12979.	3.2	13
14	Reversal and Prevention of the Respiratory-Depressant Effects of Heroin by the Novel Î¼-Opioid Receptor Antagonist Methocinnamox in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 229-236.	1.3	23
15	¹⁹F and ¹H quantitative-NMR spectroscopic analysis of fluorinated third-generation synthetic cannabinoids. Analytical Methods, 2019, 11, 3090-3100.	1.3	14
16	Simultaneous Transdermal Delivery of Buprenorphine Hydrochloride and Naltrexone Hydrochloride by Iontophoresis. Molecular Pharmaceutics, 2019, 16, 2808-2816.	2.3	14
17	Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys. Neuropsychopharmacology, 2019, 44, 1476-1484.	2.8	12
18	BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates. British Journal of Anaesthesia, 2019, 122, e146-e156.	1.5	42

#	Article	IF	Citations
19	Methocinnamox Produces Long-Lasting Antagonism of the Behavioral Effects of Âμ-Opioid Receptor Agonists but Not Prolonged Precipitated Withdrawal in Rats. Journal of Pharmacology and Experimental Therapeutics, 2019, 371, 507-516.	1.3	12
20	Long-Lasting Effects of Methocinnamox on Opioid Self-Administration in Rhesus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 88-99.	1.3	28
21	Buprenorphine C7â€Esters with Improved Nociceptin Receptor Agonist Potency as Analgesics. FASEB Journal, 2019, 33, 663.16.	0.2	0
22	Methocinnamox: Sustained Antagonism of the Antinociceptive Effects of Morphine and Not Spiradoline in Rats. FASEB Journal, 2019, 33, 498.10.	0.2	1
23	Methocinnamox (MCAM) is an Effective Longâ€Term Antagonist of Peripheral Mu, but not Kappa or Delta Opioid Receptors In Vivo. FASEB Journal, 2019, 33, 498.9.	0.2	1
24	Methocinnamox (MCAM) is a Selective, Long Acting Antagonist at Mu Opioid Receptors In Vitro. FASEB Journal, 2019, 33, 498.8.	0.2	1
25	Additive Effects of 3,4-Methylenedioxymethamphetamine (MDMA) and Compassionate Imagery on Self-Compassion in Recreational Users of Ecstasy. Mindfulness, 2018, 9, 1134-1145.	1.6	18
26	Evaluation of ¹¹C-BU99008, a PET Ligand for the Imidazoline₂ Binding Site in Human Brain. Journal of Nuclear Medicine, 2018, 59, 1597-1602.	2.8	61
27	Antidepressantâ€like effects of BU10119, a novel buprenorphine analogue with mixed Î¹/Î¼ receptor antagonist properties, in mice. British Journal of Pharmacology, 2018, 175, 2869-2880.	2.7	24
28	Targeting opioid receptor signaling in depression: do we need selective Î¹ opioid receptor antagonists?. Neuronal Signaling, 2018, 2, NS20170145.	1.7	12
29	Synthesis, Biological Evaluation, and SAR Studies of 14Î²-phenylacetyl Substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones Derivatives: Ligands With Mixed NOP and Opioid Receptor Profile. Frontiers in Psychiatry, 2018, 9, 430.	1.3	3
30	The novel Î¼â€opioid receptor agonist PZM21 depresses respiration and induces tolerance to antinociception. British Journal of Pharmacology, 2018, 175, 2653-2661.	2.7	142
31	The novel, pseudo-irreversible mu opioid receptor antagonist SH-1 attenuates the reinforcing and respiratory-depressant effects of heroin in rhesus monkeys. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-1-70.	0.0	0
32	Methyl-orvinolâ€"Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome. Pharmacological Reports, 2017, 69, 350-357.	1.5	9
33	Behavioural tasks sensitive to acute abstinence and predictive of smoking cessation success: a systematic review and metaâ€analysis. Addiction, 2016, 111, 2134-2144.	1.7	15
34	A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5511-8.	3.3	87
35	Combined administration of buprenorphine and naltrexone produces antidepressant-like effects in mice. Journal of Psychopharmacology, 2015, 29, 812-821.	2.0	45
36	1H, 13C, 15N HMBC, and 19F NMR spectroscopic characterisation of seized flephedrone, cut with benzocaine. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 535-538.	1.4	8

#	Article	IF	Citations
37	<scp>BU</scp>08073 a buprenorphine analogue with partial agonist activity at Î¼â€receptors in vitro but longâ€lasting opioid antagonist activity in vivo in mice. British Journal of Pharmacology, 2015, 172, 668-680.	2.7	32
38	Structural insights into Âµ-opioid receptor activation. Nature, 2015, 524, 315-321.	13.7	743
39	C7Î²-Methyl Analogues of the Orvinols: The Discovery of Kappa Opioid Antagonists with Nociceptin/Orphanin FQ Peptide (NOP) Receptor Partial Agonism and Low, or Zero, Efficacy at Mu Opioid Receptors. Journal of Medicinal Chemistry, 2015, 58, 4242-4249.	2.9	23
40	Selectivity and Anti-Parkinsonâ€™s Potential of Thiadiazolidinone RGS4 Inhibitors. ACS Chemical Neuroscience, 2015, 6, 911-919.	1.7	41
41	Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. European Journal of Pharmacology, 2015, 765, 582-590.	1.7	19
42	Role of G Proteinâ€“Coupled Receptor Kinases 2 and 3 inÎ¼-Opioid Receptor Desensitization and Internalization. Molecular Pharmacology, 2015, 88, 347-356.	1.0	81
43	BU08028 Displays a Promising Therapeutic Profile as an Analgesic in Monkeys. FASEB Journal, 2015, 29, 616.2.	0.2	1
44	Novel approaches for the treatment of psychostimulant and opioid abuse â€“ focus on opioid receptor-based therapies. Expert Opinion on Drug Discovery, 2014, 9, 1333-1344.	2.5	18
45	A nonâ€rewarding, nonâ€aversive buprenorphine/naltrexone combination attenuates drugâ€primed reinstatement to cocaine and morphine in rats in a conditioned place preference paradigm. Addiction Biology, 2014, 19, 575-586.	1.4	37
46	Loop diuretics are openâ€channel blockers of the cystic fibrosis transmembrane conductance regulator with distinct kinetics. British Journal of Pharmacology, 2014, 171, 265-278.	2.7	3
47	Palladiumâ€mediated oxidative carbonylation reactions for the synthesis of ¹¹Câ€radiolabelled ureas. Journal of Labelled Compounds and Radiopharmaceuticals, 2014, 57, 202-208.	0.5	21
48	Selectively Promiscuous Opioid Ligands: Discovery of High Affinity/Low Efficacy Opioid Ligands with Substantial Nociceptin Opioid Peptide Receptor Affinity. Journal of Medicinal Chemistry, 2014, 57, 4049-4057.	2.9	20
49	Evaluation of ¹¹C-BU99008, a PET Ligand for the Imidazoline₂ Binding Sites in Rhesus Brain. Journal of Nuclear Medicine, 2014, 55, 838-844.	2.8	44
50	Pyrrolo- and pyridomorphinans: Non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists. Bioorganic and Medicinal Chemistry, 2014, 22, 4067-4072.	1.4	2
51	Characterization of BU09059: A Novel Potent Selective Îº-Receptor Antagonist. ACS Chemical Neuroscience, 2014, 5, 177-184.	1.7	13
52	Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms. European Journal of Pharmacology, 2014, 736, 63-69.	1.7	25
53	Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity. Journal of Medicinal Chemistry, 2013, 56, 3207-3216.	2.9	41
54	Pharmacology of Mixed NOP/Mu Ligands. ACS Symposium Series, 2013, , 369-391.	0.5	1

#	Article	IF	Citations
55	Buprenorphine and Related Orvinols. ACS Symposium Series, 2013, , 127-144.	0.5	15
56	Effects of Spinally Administered Bifunctional Nociceptin/Orphanin FQ Peptide Receptor/Î¼-Opioid Receptor Ligands in Mouse Models of Neuropathic and Inflammatory Pain. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 11-22.	1.3	56
57	Imaging Imidazoline-I₂ Binding Sites in Porcine Brain Using ¹¹C-BU99008. Journal of Nuclear Medicine, 2013, 54, 139-144.	2.8	30
58	In vivo and in vitro characterization of naltrindole-derived ligands at the Îº-opioid receptor. Journal of Psychopharmacology, 2013, 27, 192-202.	2.0	14
59	Fumaroylamino-4,5-epoxymorphinans and Related Opioids with Irreversible Î¼ Opioid Receptor Antagonist Effects. Journal of Medicinal Chemistry, 2012, 55, 9868-9874.	2.9	8
60	Evaluation and initial in vitro and ex vivo characterization of the potential positron emission tomography ligand, BU99008 (2â€²(4,5â€²Dihydroâ€²Hâ€²imidazolâ€²2â€²yl)â€²1â€²methylâ€²Hâ€²indole), for the imidazoline₂ binding site. Synapse, 2012, 66, 542-551.	2.6	42
61	Small Molecule Inhibitors of Regulators of G Protein Signaling (RGS) Proteins. ACS Medicinal Chemistry Letters, 2012, 3, 146-150.	1.3	41
62	Structural Determinants of Opioid and NOP Receptor Activity in Derivatives of Buprenorphine. Journal of Medicinal Chemistry, 2011, 54, 6531-6537.	2.9	38
63	A Nanomolar-Potency Small Molecule Inhibitor of Regulator of G-Protein Signaling Proteins. Biochemistry, 2011, 50, 3181-3192.	1.2	55
64	Microfluidic reactions using [11C]carbon monoxide solutions for the synthesis of a positron emission tomography radiotracer. Organic and Biomolecular Chemistry, 2011, 9, 3313.	1.5	70
65	The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorp (BU08028): Characterization of the In Vitro Profile and In Vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 952-961.	1.3	67
66	Reversible, Allosteric Small-Molecule Inhibitors of Regulator of G Protein Signaling Proteins. Molecular Pharmacology, 2010, 78, 524-533.	1.0	70
67	14-Amino-4,5-Epoxymorphinan Derivatives and Their Pharmacological Actions. Topics in Current Chemistry, 2010, 299, 93-119.	4.0	8
68	Synthesis and in vivo evaluation of [11C]BU99008 as a ligand for the imidazoline I2 binding site. NeuroImage, 2010, 52, S127-S128.	2.1	4
69	Synthesis and in vivo brain distribution of carbon-11-labeled Î´-opioid receptor agonists. Nuclear Medicine and Biology, 2010, 37, 989-996.	0.3	4
70	Effects of intradermal administration of endogenous opioid peptides, Î²-endorphin and dynorphinâ€A, on scratching behavior in mice. FASEB Journal, 2010, 24, .	0.2	0
71	Proerectile Effects of Dopamine D₂-Like Agonists Are Mediated by the D₃ Receptor in Rats and Mice. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 210-217.	1.3	41
72	Effects of Atypical Îº-Opioid Receptor Agonists on Intrathecal Morphine-Induced Itch and Analgesia in Primates. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 193-200.	1.3	81

#	Article	IF	Citations
73	Identification of an imidazoline binding protein: Creatine kinase and an imidazoline-2 binding site. Brain Research, 2009, 1279, 21-28.	1.1	32
74	The discriminative stimulus effects of dopamine D2- and D3-preferring agonists in rats. Psychopharmacology, 2009, 203, 317-327.	1.5	15
75	14Î²-O-Cinnamoylnaltrexone and Related Dihydrocodeinones are Mu Opioid Receptor Partial Agonists with Predominant Antagonist Activity. Journal of Medicinal Chemistry, 2009, 52, 1553-1557.	2.9	12
76	14Î²-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and Related Opioids. Further Examples of Pseudoirreversible Î¼ Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 6926-6930.	2.9	7
77	Mixed Î¹/Î¼ Opioid Receptor Agonists: The 6Î²-Naltrexamines. Journal of Medicinal Chemistry, 2009, 52, 1546-1552.	2.9	17
78	Activities of mixed NOP and Î¼â€opioid receptor ligands. British Journal of Pharmacology, 2008, 153, 609-619.	2.7	55
79	Effects of a novel kappa opioid receptor agonist, TRKâ€820, on intrathecal morphineâ€induced itch and analgesia in monkeys. FASEB Journal, 2008, 22, 712.4.	0.2	0
80	The effect of 1-(4,5-dihydro-1H-imidazol-2-yl) isoquinoline on monoamine release and turnover in the rat frontal cortex. Neuroscience Letters, 2007, 422, 109-113.	1.0	2
81	First Asymmetric Synthesis of trans-3,4-Dimethyl-4-arylpiperidines. Organic Letters, 2007, 9, 3769-3771.	2.4	9
82	Cinnamoyl Derivatives of 7Î±-Aminomethyl-6,14-endo-ethanotetrahydrothebaine and 7Î±-Aminomethyl-6,14-endo-ethanotetrahydrooripavine and Related Opioid Ligands. Journal of Medicinal Chemistry, 2007, 50, 5176-5182.	2.9	16
83	Isolation and Chemical Modification of Clerodane Diterpenoids from Salvia Species as Potential Agonists at the Î¹â€Opioid Receptor. Chemistry and Biodiversity, 2007, 4, 1586-1593.	1.0	13
84	Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. Psychopharmacology, 2007, 193, 159-170.	1.5	119
85	Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones:Â Effects of Changes to the Chain Linking of the C14-Amino Group to the Aryl Ring. Journal of Medicinal Chemistry, 2006, 49, 6104-6110.	2.9	13
86	Structural Determinants of Opioid Activity in Derivatives of 14-Aminomorphinones:Â Effect of Substitution in the Aromatic Ring of Cinnamoylaminomorphinones and Codeinones. Journal of Medicinal Chemistry, 2006, 49, 5333-5338.	2.9	20
87	In vitro and ex vivo distribution of [3H]harmane, an endogenous Î²-carboline, in rat brain. Neuropharmacology, 2006, 50, 269-276.	2.0	53
88	Synthesis of novel 1-substituted [1,3]thiazolo[3,2-a]-[1,5]benzodiazepine derivatives from 1,5-benzodiazepine-2-thiones and Î±-halogen carbonyl compounds. Journal of Heterocyclic Chemistry, 2006, 43, 979-984.	1.4	6
89	Effects of the long-lasting kappa opioid 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl) ethyl] acetamide in a drug discrimination and warm water tail-withdrawal procedure. Behavioural Pharmacology, 2005, 16, 665-670.	0.8	3
90	BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism. European Journal of Pharmacology, 2005, 509, 117-125.	1.7	28

#	Article	IF	Citations
91	Formic Acid Catalysed Rearrangement of 5?-Methyldihydrothevinols (=3,6-Dimethoxy-5,17-dimethyl-4,5-epoxy-6,14-ethanomorphinan-7-methanols): Synthesis of New Doubly Bridged Morphinan Derivatives. Chemistry and Biodiversity, 2005, 2, 215-220.	1.0	0
92	Major Effect of Pyrrolic N-Benzylation in Norbinaltorphimine, the Selective Î¹-Opioid Receptor Antagonist. Journal of Medicinal Chemistry, 2005, 48, 1676-1679.	2.9	8
93	Extension of the Nenitzescu Reaction to Simple Ketones Provides an Efficient Route to 1â€˜-Alkyl-5â€˜-hydroxynaltrindole Analogues, Potent and Selective Î´-Opioid Receptor Antagonists. Journal of Medicinal Chemistry, 2005, 48, 635-638.	2.9	18
94	The Orvinols and Related Opioids - High Affinity Ligands with Diverse Efficacy Profiles. Current Pharmaceutical Design, 2004, 10, 717-732.	0.9	81
95	Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. European Journal of Pharmacology, 2004, 499, 107-116.	1.7	44
96	Kappa-opioid receptor ligands. Expert Opinion on Therapeutic Patents, 2004, 14, 1725-1741.	2.4	9
97	Effects of Substitution on the Pyrrole N Atom in Derivatives of Tetrahydronaltrindole, Tetrahydrooxymorphindole, and a Related 4,5-Epoxyphenylpyrrolomorphinan. Journal of Medicinal Chemistry, 2004, 47, 6645-6648.	2.9	19
98	Pharmacological characterisation of novel Î±2-adrenoceptor antagonists as potential brain imaging agents. Neuropharmacology, 2004, 46, 847-855.	2.0	5
99	Identification of a New Scaffold for Opioid Receptor Antagonism Based on the 2-Amino-1,1-dimethyl-7-hydroxytetralin Pharmacophore. Journal of Medicinal Chemistry, 2004, 47, 5069-5075.	2.9	13
100	Harmane and Harmalan Are Bioactive Components of Classical Clonidine-Displacing Substanceâ€. Biochemistry, 2004, 43, 16385-16392.	1.2	36
101	Characterization of [3H]Harmane Binding to Rat Whole Brain Membranes. Annals of the New York Academy of Sciences, 2003, 1009, 175-179.	1.8	14
102	Novel Ligands for the Investigation of Imidazoline Receptors and Their Binding Proteins. Annals of the New York Academy of Sciences, 2003, 1009, 302-308.	1.8	18
103	Behavioral effects of rimcazole analogues alone and in combination with cocaine. European Journal of Pharmacology, 2003, 468, 109-119.	1.7	33
104	The 14-Alkyl- and 14-Alkenyl-5-methylindolomorphinan Series Provide -Selective Partial Opioid Agonists. Helvetica Chimica Acta, 2003, 86, 793-798.	1.0	8
105	Formic Acid Catalyzed Rearrangement of Thevinols (=4,5-Epoxy-3,6-dimethoxy-Î±,17-dimethyl-6,14-ethenomorphinan-7-methanols) and Their Vinylogous Analogues: Effects of 5Î²-Methyl Substitution. Helvetica Chimica Acta, 2003, 86, 2287-2298.	1.0	9
106	Dual Probes for the Dopamine Transporter and Ïƒ1 Receptors:â€‰ Novel Piperazinyl Alkyl-bis(4â€˜-fluorophenyl)amine Analogues as Potential Cocaine-Abuse Therapeutic Agents. Journal of Medicinal Chemistry, 2003, 46, 2589-2598.	2.9	27
107	Opioid Binding and in Vitro Profiles of a Series of 4-Hydroxy-3-methoxyindolomorphinans. Transformation of a Î´-Selective Ligand into a High Affinity Î¹-Selective Ligand by Introduction of a 5,14-Substituted Bridge. Journal of Medicinal Chemistry, 2003, 46, 3174-3177.	2.9	11
108	Guanidino N-Substituted and N,N-Disubstituted Derivatives of the Î¹-Opioid Antagonist GNTI. Journal of Medicinal Chemistry, 2003, 46, 5505-5511.	2.9	16

#	Article	IF	Citations
109	The Role of the Side Chain in Determining Relative Î´- and Î¹-Affinity in C5â€˜-Substituted Analogues of Naltrindole. Journal of Medicinal Chemistry, 2003, 46, 314-317.	2.9	17
110	Opioid Ligands Having Delayed Long-Term Antagonist Activity: Potential Pharmacotherapies for Opioid Abuse. Mini-Reviews in Medicinal Chemistry, 2003, 3, 137-144.	1.1	17
111	14-Amino, 14-Alkylamino, and 14-Acylamino Analogs of Oxymorphindole. Differential Effects on Opioid Receptor Binding and Functional Profiles. Journal of Medicinal Chemistry, 2003, 46, 1563-1566.	2.9	14
112	4â€˜-Arylpyrrolomorphinans:â€‰ Effect of a Pyrrolo-N-benzyl Substituent in Enhancing Î´-Opioid Antagonist Activity. Journal of Medicinal Chemistry, 2002, 45, 537-540.	2.9	15
113	N1â€²-fluoroethyl-naltrindole (BU97001) and N1â€²-fluoroethyl-(14-formylamino)-naltrindole (BU97018) potential Î´-opioid receptor PET ligands. Nuclear Medicine and Biology, 2002, 29, 455-462.	0.3	12
114	Michael Reactions of Benzylimines Derived from Morphinan-6-ones: Synthesis of Pyrrolo- and Pyridinomorphinans. Helvetica Chimica Acta, 2002, 85, 1790-1799.	1.0	6
115	Design and Synthesis of [(2,3-Dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as Novel Ligands Selective for the Dopamine D3Receptor Subtype. Journal of Medicinal Chemistry, 2001, 44, 3175-3186.	2.9	84
116	Î²-carboline binding to imidazoline receptors. Drug and Alcohol Dependence, 2001, 64, 203-208.	1.6	118
117	Rimcazole analogs attenuate the convulsive effects of cocaine: correlation with binding to sigma receptors rather than dopamine transporters. Neuropharmacology, 2001, 41, 878-886.	2.0	55
118	Selective Î´-opioid receptor ligands: potential PET ligands based on naltrindole. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 939-943.	1.0	19
119	[3-cis-3,5-Dimethyl-(1-piperazinyl)alkyl]-bis-(4â€²-fluorophenyl)amine analogues as novel probes for the dopamine transporter. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 3169-3173.	1.0	13
120	Structural Determinants of Opioid Activity in the Orvinols and Related Structures. Ethers of 7,8-Cyclopenta-Fused Analogs of Buprenorphine. Helvetica Chimica Acta, 2000, 83, 687-693.	1.0	5
121	Cinnamoyl Derivatives of 7Î±-Amino- and 7Î±-(Aminomethyl)-N-(cyclopropylmethyl)-6,14-endo-ethanotetrahydronororipavines are High-Potency Opioid Antagonists. Helvetica Chimica Acta, 2000, 83, 3122-3130.	1.0	8
122	Perchloric acid induced epimerisation of the thevinones: an improved synthesis of 7Î²-dihydrothevinones. Tetrahedron Letters, 2000, 41, 7571-7576.	0.7	6
123	Probes for imidazoline binding sites: synthesis and evaluation of a selective, irreversible I 2 ligand. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 605-607.	1.0	15
124	Selective Î¹-opioid antagonists related to naltrindole. effect of side-chain spacer in the 5â€²-amidinoalkyl series. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 2259-2261.	1.0	18
125	Structural Determinants of Opioid Activity in the Orvinols and Related Structures:Â Ethers of Orvinol and Isoorvinol. Journal of Medicinal Chemistry, 2000, 43, 1852-1857.	2.9	14
126	3-Deoxyclocinnamox:â€‰ The First High-Affinity, Nonpeptide Î¼-Opioid Antagonist Lacking a Phenolic Hydroxyl Group. Journal of Medicinal Chemistry, 2000, 43, 3348-3350.	2.9	23

#	Article	IF	Citations
127	Structural Determinants of Efficacy for Î¹ Opioid Receptors in the Orvinol Series:Â 7,7-Spiro Analogues of Buprenorphine. Journal of Medicinal Chemistry, 2000, 43, 139-141.	2.9	21
128	Acid catalysed rearrangements of the thevinols: The mechanism of furanocodide formation. Tetrahedron Letters, 1999, 40, 1795-1798.	0.7	4
129	Ring constrained analogues of the orvinols: The furanomorphides. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 831-834.	1.0	11
130	Novel Selective Compounds for the Investigation of Imidazoline Receptorsa. Annals of the New York Academy of Sciences, 1999, 881, 81-91.	1.8	72
131	Derivatives of Flavonepenthone: Kappa Opioid Receptor Selectivity in anN-Methylmorphinan. Helvetica Chimica Acta, 1999, 82, 1721-1727.	1.0	5
132	6-O-Demethylation of the Thevinols with Lithium Aluminium Hydride: Selective Demethylation of a Tertiary Alkyl Methyl Ether in the Presence of an Aryl Methyl Ether. Helvetica Chimica Acta, 1999, 82, 1978-1980.	1.0	13
133	Structureâ^'Activity Relationships at the Monoamine Transporters and Ïƒ Receptors for a Novel Series of 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)-propyl]carbazole (Rimcazole) Analogues. Journal of Medicinal Chemistry, 1999, 42, 4446-4455.	2.9	46
134	A Diastereospecific Synthesis of 2-Methyl-5Î²-phenyl-5Î±-carbethoxy-2- azabicyclo[2.2.1]heptane:Â A Ring-Constrained Analogue of Meperidine. Journal of Organic Chemistry, 1998, 63, 418-419.	1.7	6
135	3-Alkyl Ethers of Clocinnamox:Â Delayed Long-Term Î¼-Antagonists with Variable Î¼ Efficacy. Journal of Medicinal Chemistry, 1998, 41, 3493-3498.	2.9	19
136	Isothiocyanate Derivatives of 9-[3-(cis-3,5-Dimethyl-1-piperazinyl)propyl]- carbazole (Rimcazole):Â Irreversible Ligands for the Dopamine Transporter. Journal of Medicinal Chemistry, 1997, 40, 4340-4346.	2.9	24
137	Identification of ligands selective for central I2-imidazoline binding sites. Neurochemistry International, 1997, 30, 47-53.	1.9	39
138	Morphinan cyclic imines and pyrrolidines containing a constrained phenyl group: High affinity opioid agonists. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 2969-2974.	1.0	19
139	Latent inhibitors part 11. The synthesis of 5-spirocyclopropyl dihydroorotic acid. Tetrahedron, 1995, 51, 865-870.	1.0	14
140	Methylation of the enolates of thevinone and some analogues. Tetrahedron, 1995, 51, 9681-9698.	1.0	13
141	Ring constrained analogues of the thevinones; Diels-Alder reactions of thebaines with 1-indenone and methylene cycloalkanones. Tetrahedron Letters, 1995, 36, 1689-1692.	0.7	12
142	Functional Studies of Specific Imidazoline-2 Receptor Ligands. Annals of the New York Academy of Sciences, 1995, 763, 125-139.	1.8	121
143	Latent inhibitors Part 10. The inhibition of carboxypeptidase a by tetrapeptide analogues based on 1-aminocyclopropane carboxylic acid. Tetrahedron, 1994, 50, 9729-9742.	1.0	9